Not all KU technology is as big a commercial success as Abilify®, but it’s a great example of how innovation, research and protecting intellectual property are helping society and funding further research at KU.
Cancer Survivorship Training, Inc. is a provider of online and mobile resources and education to health care professionals to help them better treat and advise cancer survivors.
CyDex, Inc. was established to license and commercialize modified cyclodextrins for use in drug development and formulation. The series of anionically charged sulfobutyl ether beta-cyclodextrins (SBE-CDs) were originally synthesized and patented by scientists in the Higuchi Biosciences Center for Drug Delivery Research. CyDex has an exclusive license to the SBE Cyclodextrins. Their lead compound, Captisol®, enabled six FDA-approved products, including Onyx Pharmaceuticals’ Kyprolis®, Baxter International’s Nexterone®, BMS’s injectable Abilify, product, injectable Cerenia, also sold by Pfizer. There are also many more Captisol-enabled products in clinical development. Cydex was acquired by Ligand Pharmaceuticals in 2011. Ligand has offices in Bioscience and Technology Business Center (BTBC) incubator on the Lawrence campus.
HylaPharm is a drug delivery company now producing its patented HylaPlat technology, which delivers chemotherapy drugs directly to cancer cells in tumors and nearby lymph nodes while limiting drug exposure in kidneys, nerves and auditory organs. By limiting exposure in these surrounding areas, HylaPlat enables targeted treatments with fewer side effects.
KanPro Research, LLC is a contract research organization (CRO) headquartered in the Bioscience & Technology Business Center at the University of Kansas. The company specializes in recombinant protein expression and purification from mammalian and cell-free systems. KanPro seeks contract research partnerships with academic and industrial researchers. The company has special expertise in producing challenging proteins including those that have previously failed. KanPro Research also manufactures, tests biochemical reagents, kits and equipment and provides advice and consultation services.
Savara Pharmaceuticals is an early stage biotechnology company established to commercialize the NanoCluster dry powder aerosol formulation technology? The NanoCluster formulation technology is a platform technology with broad applications from respiratory medicine to vaccines and provides critical Life-Cycle-Management opportunities through product reformulation.